ライフサイエンスコーパス: capsular

1 h asymptomatic and symptomatic patients, and capsular adhesions at the anterior femoral neck were pre

2 Results Capsular adhesions at the anterior femoral neck were pre

3 ence of abnormal imaging findings, including capsular adhesions at the femoral neck, obliteration of

4 oughput screen for gene products involved in capsular alpha-glucan production.

5 infants were obtained in parallel and their capsular and pilus types were identified by serological

6 ciation of breast milk GBS serotype-specific capsular antibodies and risks for invasive disease in in

7 en natural secretory immunoglobulin A (sIgA) capsular antibodies in breast milk and the occurrence of

8 lacentally transferred GBS serotype-specific capsular antibodies in the infants and their immune resp

9 Breast milk sIgA capsular antibodies were associated with lower risks for

10 enteral administration of serotype-specific capsular antibodies.

11 roup B streptococcus (GBS) serotype-specific capsular antibody concentrations are correlated with sus

12 vaccine that produces both the protective F1 capsular antigen of Yersinia pestis and the LcrV protein

13 ytosis that is independent of polysaccharide capsular antigen.

14 lasticity, antibiotic resistance and extreme capsular antigenic variation complicates the design of e

15 The dimeric capsular assemblies display the spacer-length-dependent

16 These icosahedral and capsular assemblies reveal at high-resolution the molecu

17 onsistent with the importance of vesicles in capsular assembly.

18 gesting that this is an initiation point for capsular assembly.

19 To enhance capsular association strength, tuning the XB donor is mo

20 The IOL was stable in the capsular bag as demonstrated by tilt and decentration me

21 the vitrectomized eyes with reduced zonular/capsular bag complex integrity to the vitrectomized pseu

22 managed with PPV and removal of the IOL and capsular bag had better visual outcomes.

23 L fixation and its resulting position in the capsular bag have a significant effect on the effective

24 ntation, with successful preservation of the capsular bag in 90% of eligible cases, especially in eye

25 educed cell coverage in both closed and open capsular bag models.

26 nts (56%) who had intraocular lens (IOL) and capsular bag removals had better final BCVAs than those

27 ses were placed together with the IOL in the capsular bag using an injection system or were fixed by

28 The capsular bag was preserved in 43 eyes (91.5%).

29 l-sutured implant and an implantation in the capsular bag were both found to prevent the iris retract

30 nted into residual lens tissue, known as the capsular bag, following cataract removal.

31 a posterior chamber intraocular lens in the capsular bag, with a capsular tension ring due to partia

32 ain outcome measure was the retention of the capsular bag.

33 Three different IOLs were implanted in the capsular bag.

34 Furthermore, immunofluorescence staining of capsular bags for the fibrotic markers f-actin, fibronec

35 Twenty cadaver capsular bags from 10 human donors were used, with the n

36 Explanted capsular bags from 3 of these patients were compared wit

37 Five capsular bags of 3 donors served as controls without IOL

38 Histologic examination of the explanted capsular bags revealed a paucicellular membrane that cov

39 omized pseudophakic eyes with intact zonular/capsular bags, the former were significantly associated

40 een the Clareon vs. the AcrySof IOL in human capsular bags.

41 siologic features of uveal biocompatibility, capsular biocompatibility, and postoperative IOL opacifi

42 ade 1, both features were grade 2, and frank capsular breach were grade 3.

43 ows: curvilinear contact length of 1.5 cm or capsular bulge and irregularity were grade 1, both featu

44 curvilinear contact length, 88 of 208 (42%); capsular bulge and irregularity, 78 of 175 (45%); and EP

45 C8 targets capsular carbohydrate on the bacterial surface, enhancin

46 typical bilateral symmetrical posterior sub capsular cataract with punctate iridescent opacities in

47 T receptors (OXTRs) has been detected in the capsular (CeC) and lateral (CeL) nucleus of the central

48 >10 mum with distinct but poorly understood capsular characteristics.

49 lens dislocation may result from progressive capsular contraction secondary to retinal detachment-ind

50 ave been widely studied, such as rupture and capsular contraction.

51 Capsular contracture (III/IV) occurs in 7.2% of primary

52 nt was nearly 4 times as likely to result in capsular contracture (p < 0.01).

53 r for saline (2.5% vs. 0.5%, P < 0.001), and capsular contracture higher for silicone (5.0% vs. 2.8%,

54 Capsular contracture is a common adverse outcome followi

55 Capsular contracture rate was greater in the subpectoral

56 Revision for capsular contracture was similar between the 2 cohorts (

57 Signs of capsular contracture were assessed using clinic notes an

58 In the periodontal lesions, both capsular-defective knockout mutant strains of P. gingiva

59 ion to vascularization of the lens through a capsular dehiscence, other causes are explored, includin

60 lid-type synovitis, synovial thickening, and capsular dehiscence.

61 In this respect, a previously proposed capsular device able to control the release performance

62 Reader 1 detected superior capsular edema in 15 of 20 patients with SSI (75%) and t

63 out SSI (7%), and reader 2 detected superior capsular edema in 17 of 20 patients with SSI (85%) and 2

64 ations were made regarding uniformity of the capsular edge and the presence of irregularities that ma

65 y sampling showed a generally uniform rolled capsular edge, but interspersed with areas of irregulari

66 at TTPA also exhibits lytic activity towards capsular exopolysaccharide (EPS) of the multiresistant c

67 in corneal edema, AC inflammatory reaction, capsular fibrosis, ACO, and PCO.

68 ol microbiota and brain function in HE after capsular FMT in a randomized, single-blind, placebo-cont

69 ght the difficulties in the serogrouping and capsular genogrouping of meningococcal carriage isolates

70 Capsular genogroups detected by broth culture were genog

71 in a 1:1 ratio, to receive either a TCV or a capsular group A meningococcal conjugate vaccine (MenA)

72 The capsular group B meningococcal (MenB) four component vac

73 o provide strain-specific protection against capsular group B Neisseria meningitidis infections, but

74 eceived the combined H influenzae type b and capsular group C Neisseria meningitidis tetanus toxoid c

75 Maternal anti-capsular IgG concentrations above 1 microg/mL mediated G

76 Moreover, maternal anti-capsular IgG concentrations showed a significant correla

77 GBS serotype-specific anti-capsular IgG was measured on maternal and cord blood/inf

78 (HR, 2.38; 95% CI, 1.27-4.48; P = .01), and capsular invasion (HR, 1.96; 95% CI, 1.02-3.74; P = .04)

79 However, capsular invasion and tumor mass have a more aggressive

80 assess for microscopic tumor involvement and capsular invasion.

81 he greatest increase in CDFS3 over time (eg, capsular invasion: 28%-88%, Delta60% vs no capsular inva

82 , capsular invasion: 28%-88%, Delta60% vs no capsular invasion: 51%-87%, Delta36%).

83 Capsular lamellar separation and anterior zonular disrup

84 on histologic findings consisting of diffuse capsular lamellar separation and anterior zonular disrup

85 nation with the biogenesis of the protective capsular layer.

86 ptive cascades in the joint by degrading the capsular ligament's matrix and activating innervating pa

87 type ST258 clade 1 (86%) with variations in capsular locus (cps) and prophage content.

88 nular support, defects, or missing posterior capsular membranes and vitrectomy histories present a hi

89 are good antigens for vaccine production and capsular oligosaccharides conjugate vaccines are proven

90 s a high incidence of postsurgical posterior capsular opacification (18/19, 95%).

91 mation, corneal endothelial damage, anterior capsular opacification (ACO), and posterior capsular opa

92 Evaluation of posterior capsular opacification (EPCO), posterior capsule opacity

93 application for the management of posterior capsular opacification (PCO).

94 capsular opacification (ACO), and posterior capsular opacification (PCO).

95 The most common AE was posterior capsular opacification (PCO; 748 eyes, incidence 4.0%).

96 cuity, incidence of macular edema, posterior capsular opacification, epiretinal membrane, and intraoc

97 ) because the technique was unable to detect capsular or vascular invasion, although the specificity

98 ajor sensory input region of the lateral and capsular part of the CeA (CeL/C), and four principal out

99 Solid-phase fixation of the engineered capsular polymerases enabled rapid production of capsula

100 st step, the elongation modes of recombinant capsular polymerases from Neisseria meningitidis serogro

101 e solution behaviour of native and activated capsular polyribosylribitol (PRP) polysaccharides extrac

102 ategy was selected to elicit opsonizing anti-capsular polysaccharide (anti-CPS) IgG antibodies.

103 Capsular polysaccharide (CP) biosynthesis in Staphylococ

104 lycopolymers, such as wall teichoic acid and capsular polysaccharide (CP).

105 the Neisseria meningitidis serogroup W (NmW) capsular polysaccharide (CPS) and is a required structur

106 ed with mutations in the putative E. faecium capsular polysaccharide (cps) biosynthetic locus, with d

107 hogenesis, expression of a surface-localized capsular polysaccharide (CPS) can be critical for surviv

108 In the present study, the 6-deoxyheptan capsular polysaccharide (CPS) from B. pseudomallei was p

109 mmunoglobulin G (IgG) antibodies against the capsular polysaccharide (CPS) offer S. pneumoniae seroty

110 l in blood, of which 75% were members of the capsular polysaccharide (cps) operon.

111 hetic glycans resembling portions of the ST2 capsular polysaccharide (CPS) repeating unit were used t

112 Glycoconjugate vaccines based on isolated capsular polysaccharide (CPS) save millions of lives ann

113 opy analyses indicated a near absence of the capsular polysaccharide (CPS) when S. pneumoniae was gro

114 C. jejuni is known to produce capsular polysaccharide (CPS), but the specific role tha

115 A GBS type III capsular polysaccharide (CPS)-tetanus toxoid conjugate (

116 Oral streptococci often harbor capsular polysaccharide (PS) synthesis loci (cps).

117 ns (O-polysaccharide [OPS] and 6-deoxyheptan capsular polysaccharide [CPS]) and two crude antigens (w

118 he gut commensal Bacteroides fragilis or its capsular polysaccharide A (PSA) can prevent various peri

119 treptococcus pneumoniae target the bacterial capsular polysaccharide and confer no protection against

120 Despite the immense variation in capsular polysaccharide and exopolysaccharide structures

121 Insights into the interactions between the capsular polysaccharide and its transporter and the mech

122 f the hexasaccharide repeating unit from its capsular polysaccharide and related sequences.

123 tigated the role of Abs to the mycobacterial capsular polysaccharide arabinomannan (AM) and its oligo

124 f polyclonal IgG against the M. tuberculosis capsular polysaccharide arabinomannan (AM).

125 Vaccines based on the Vi capsular polysaccharide are licensed or in development a

126 uces capsular polysaccharide identical to 6B capsular polysaccharide as determined by one-dimensional

127 are transporters implicated in O antigen and capsular polysaccharide biosyntheses with those facilita

128 First, the entire 24-kb capsular polysaccharide biosynthesis locus, which is ess

129 One spot comprising a mixture of capsular polysaccharide biosynthesis protein and other p

130 A-85/14 to confirm the presence of a unique capsular polysaccharide biosynthetic locus.

131 Presence of serotype-specific capsular polysaccharide cell-mediated immunity contribut

132 roup B Streptococcus (GBS) serotype-specific capsular polysaccharide cellular immunity, measured with

133 Capsular polysaccharide conjugate vaccine GBS6 was desig

134 Capsular polysaccharide conjugate vaccines have been tes

135 tions (Ia, Ib, II-IX), and current candidate capsular polysaccharide conjugate vaccines target only a

136 A 20-valent PCV (PCV20) containing capsular polysaccharide conjugates of serotypes present

137 he structural basis of immune recognition of capsular polysaccharide epitopes can aid in the design o

138 in the design of novel therapeutics to block capsular polysaccharide export.

139 a protective monoclonal antibody and a MenA capsular polysaccharide fragment were further elucidated

140 catalytic 18B7 antibody increases release of capsular polysaccharide from fungal cells.

141 multibranched hexasaccharide related to the capsular polysaccharide from Streptococcus pneumoniae ty

142 e element (ACME), and a specific mutation in capsular polysaccharide gene cap5E Although the PVL-enco

143 used to study the contributions of bacterial capsular polysaccharide I (CPS I) to virulence during ac

144 res of the putative serotype 6E but produces capsular polysaccharide identical to 6B capsular polysac

145 Its capsular polysaccharide is essential for systemic virule

146 in the Campylobacter jejuni NCTC11168 (HS:2) capsular polysaccharide is reported.

147 It produces a capsular polysaccharide known as "Vi antigen," which is

148 Vaccination with glycoconjugates of MenA capsular polysaccharide led to an almost complete elimin

149 mutant (AB307.30) was shown, suggesting that capsular polysaccharide mediated the inhibition of MAb b

150 One obstacle is that the capsular polysaccharide of a dominated Klebsiella pneumo

151 ther bacterial cell wall polymers, including capsular polysaccharide of streptococcal species and ara

152 ainst the 23F serotype of the pneumonococcal capsular polysaccharide of Streptococcus pneumoniae and

153 an antigenic carrier protein coupled to the capsular polysaccharide of the bacterial pathogen, are t

154 whereas the Wzx/Wzy-dependent streptococcal capsular polysaccharide pathways instead require an alph

155 anic phosphate (Pi) metabolism in modulating capsular polysaccharide production.

156 s a disease-causing serotype, the associated capsular polysaccharide remains poorly characterized.

157 ynthesis of the Staphylococcus aureus type 5 capsular polysaccharide repeating unit, a trisaccharide

158 emistry taking place at the interface of the capsular polysaccharide repeating units, described herei

159 e connection point of the repeating units of capsular polysaccharide S. aureus serotype 5 (CP5) and s

160 are not fully defined, but overproduction of capsular polysaccharide significantly impedes host clear

161 Although its capsular polysaccharide structure has not been elucidate

162 d very small amounts of fragments of the K30 capsular polysaccharide substrate reveal the translocati

163 , such as the overproduction of colanic acid capsular polysaccharide that defends against a wide arra

164 GBS bacteria are surrounded by a thick capsular polysaccharide that is a potent inhibitor of co

165 Covalent linkage of the bacterial capsular polysaccharide to a carrier protein provides CD

166 Our results indicate the importance of the capsular polysaccharide to G. parasuis virulence as well

167 in vitro experiments, using an inhibitor of capsular polysaccharide transport, enabled potent bacter

168 nserted in agrC, P3.1 regained production of capsular polysaccharide type 5 (CP5) and staphyloxanthin

169 synthesis of the repeating unit of S. aureus capsular polysaccharide type 5 equipped with capping met

170 ride repeating unit of Staphylococcus aureus capsular polysaccharide type 5, which is also a potentia

171 Capsular polysaccharide vaccines are available against m

172 Capsular polysaccharide was also protective against comp

173 p. capri or an engineered mutant lacking the capsular polysaccharide, galactofuranose.

174 ular glucuronoxylomannan (GXM), the major Cn capsular polysaccharide, LPS-induced nuclear translocati

175 are characterized into 15 serovars by their capsular polysaccharide, which has shown a correlation w

176 ecules-peptidoglycan, lipopolysaccharide and capsular polysaccharide-either simultaneously or individ

177 presence of a specific IgG1 to C. neoformans capsular polysaccharide.

178 ired immunoglobulin G (IgG) responses to GBS capsular polysaccharides (CPS) and pilus proteins in Eur

179 Bacterial capsular polysaccharides (CPS) are complex carbohydrate

180 des, including lipopolysaccharides (LPS) and capsular polysaccharides (CPS), are implicated in the ad

181 Bacteria express multiple diverse capsular polysaccharides (CPSs) for protection against e

182 Capsular polysaccharides (CPSs) play multiple roles in p

183 Streptococcus pneumoniae expresses capsular polysaccharides (CPSs) to protect itself from o

184 cteristically produce several phase-variable capsular polysaccharides (CPSs), but their contributions

185 acteria express surface carbohydrates called capsular polysaccharides (CPSs).

186 Over 90 serologically distinct pneumococcal capsular polysaccharides (serotypes) are recognized, but

187 Zwitterionic capsular polysaccharides (ZPSs) are bacterial products t

188 id (beta-Kdo) glycosides are mainly found in capsular polysaccharides and extracellular exopolysaccha

189 Although recent studies have shown that shed capsular polysaccharides and intact extracellular Cn can

190 These results demonstrate that capsular polysaccharides and intact intracellular yeast

191 mans worldwide and contains virulence factor capsular polysaccharides and lipopolysaccharides linked

192 n of biofilms and exopolysaccharides such as capsular polysaccharides and the biocontrol of phytopath

193 coccal native, micro-fluidized and activated capsular polysaccharides and their glycoconjugates - in

194 atic steps involved in the production of the capsular polysaccharides are emerging, information regar

195 Although capsular polysaccharides are good antigens for vaccine p

196 Capsular polysaccharides are important virulence factors

197 Bacterial capsular polysaccharides are important virulence factors

198 tly, it has been shown that a large group of capsular polysaccharides from Gram-negative bacteria, pr

199 eptococcus pneumoniae uses vaccines based on capsular polysaccharides from selected serotypes and has

200 Capsular polysaccharides from several important Gram-neg

201 n this study, we successfully synthesized K2 capsular polysaccharides from tetra- to octasaccharides

202 Capsular polysaccharides have been confirmed to be an im

203 e virulence-determining glycan motifs in the capsular polysaccharides of bacterial pathogens.

204 xy-beta-d-ido-heptopyranoside related to the capsular polysaccharides of C. jejuni HS:4 is very remar

205 uatorial glycosides such as are found in the capsular polysaccharides of numerous pathogenic bacteria

206 t surface of this cell envelope is formed by capsular polysaccharides that play an important role in

207 charide of beta-Kdo residues links "group 2" capsular polysaccharides to (lyso)phosphatidylglycerol.

208 Capsular polysaccharides were isolated, oxidized using s

209 ular polymerases enabled rapid production of capsular polysaccharides with high yield and purity.

210 s and also to bacterial lipopolysaccharides, capsular polysaccharides, and lipoarabinomannans that co

211 plained by binding to lipopolysaccharides or capsular polysaccharides, but in other cases they sugges

212 ctively exhibited a strong overproduction of capsular polysaccharides, including alpha-glucan and ara

213 Many bacteria produce abundant long-chain capsular polysaccharides, which can maintain a strong as

214 d class-switched IgG antibodies to microbial capsular polysaccharides, which decreased in PTX3-defici

215 tivating pathogens and purification of their capsular polysaccharides.

216 m-negative bacteria is composed of bacterial capsular polysaccharides.

217 12F, and Staphylococcus aureus types 5 and 8 capsular polysaccharides.

218 sm applies to conjugates prepared from other capsular polysaccharides.

219 sly been derived using purified GXM or whole capsular preparations as antigens.

220 omplement-mediated opsonophagocytosis due to capsular production.

221 proper oxidation and polymerization of sperm capsular proteins and malformation of the mitochondrial

222 covalently associated with cell wells (e.g., capsular PS (CPS)).

223 rain D39 both produce structurally identical capsular PS, and their genetic backgrounds influence the

224 rain, D39, both produce chemically identical capsular PS.

225 anterior-posterior, dorsal-ventral, and core-capsular relationships.

226 ), 191 (94%) of 203 participants assigned to capsular release (40.3 points, 38.9 to 41.7), and 93 (94

227 were 2.01 points (0.10 to 3.91) between the capsular release and manipulation groups, 3.06 points (0

228 n groups, 3.06 points (0.71 to 5.41) between capsular release and physiotherapy, and 1.05 points (-1.

229 ht serious adverse events were reported with capsular release and two with manipulation.

230 ipulation under anaesthesia and arthroscopic capsular release are costly and invasive treatments for

231 Arthoscopic capsular release carried higher risks, and manipulation

232 with 0.1366 for physiotherapy and 0.0002 for capsular release).

233 Arthroscopic capsular release, also done under general anaesthesia, i

234 manipulation under anaesthesia, arthroscopic capsular release, or early structured physiotherapy.

235 urgery, or 4 points between manipulation and capsular release.

236 ning electron microscopy and ultrastructural capsular remnants by transmission electron microscopy.

237 near future, such a device will be part of a capsular ring.

238 effect of FMT without antibiotics using the capsular route requires investigation.

239 Here we show that capsular RSPO3 signals to the underlying steroidogenic c

240 ontrol (n = 2), ocular movement resulting in capsular rupture (n = 2), or death (n = 1) allegedly rel

241 re were no differences in rates of posterior capsular rupture (P = 0.918), overall postoperative comp

242 To investigate the risk of posterior capsular rupture (PCR) during cataract surgery in eyes w

243 mary outcomes included the risk of posterior capsular rupture (PCR), ultrasound time, energy, and com

244 SICS), as well as in patients with posterior capsular rupture (PCR).

245 For patients with a perioperative capsular rupture of the lens (the major risk factor for

246 ities, systemic comorbidities, and posterior capsular rupture status.

247 Posterior capsular rupture was associated with a 3.68-fold increas

248 and its use for patients with perioperative capsular rupture where the risk of POE is dramatically i

249 ror (MAE), rates of intraoperative posterior capsular rupture, and postoperative complications were e

250 Tip occlusion is not a risk factor for capsular rupture, as all breaks in the capsular surrogat

251 for patients with or without a perioperative capsular rupture.

252 lls of Gram-negative Neisseria meningitidis, capsular serogroup C (MenC) or Gram-positive group B Str

253 The global drug-susceptible capsular serotype 12F, clonal complex 218 caused several

254 ile others (such as the associations between capsular serotype and lineage) remain in continuous flux

255 Associations exist between lineage and capsular serotype but these can be easily perturbed, suc

256 Capsular serotype Ia, Ib, III, and V sIgA antibody conce

257 Group B streptococcus (GBS) capsular serotypes are major determinants of virulence a

258 rvirulent strains belonging to the K1 and K2 capsular serotypes, predominantly in eastern Asia.

259 ly diverse, exhibiting a variety of distinct capsular serotypes.

260 sent and where the perimeter of CD169(+) sub capsular sinus macrophages was disrupted.

261 ically-intact bacteria within the glomerular capsular space and tubular lumens.

262 ing cells into the subcutaneous and subrenal capsular space resulted in self-organization of donor-de

263 The vaccine was well tolerated and induced capsular-specific antibody responses, in non-pregnant an

264 Initial capsular splits occur along the insertions of disrupted

265 These data suggest that lymph node capsular status is an important prognostic factor and sh

266 found to template an otherwise inaccessible capsular structure in a manner usually associated with s

267 patients (222 males and 98 females) without capsular support in which we performed RPICIOL implantat

268 intraocular lens in cases of aphakia without capsular support is debated.

269 ICIOL) in several aphakic conditions without capsular support.

270 , however, this epitope redistributes to the capsular surface in titan cells, a recently characterize

271 uscle and underlying the mesothelial/serosal/capsular surfaces of every major organ.

272 r for capsular rupture, as all breaks in the capsular surrogate occurred with tip contact.

273 akage rates were calculated by analyzing the capsular surrogate under a surgical microscope.

274 Genotyping suggests that capsular switching has occurred between MDR vaccine sero

275 ll proportion of isolates showed evidence of capsular switching in both periods.

276 e considered for inclusion, with evidence of capsular switching in CC17 strains.

277 Toronto, which revealed multiple episodes of capsular switching.

278 d for monitoring for serotype replacement or capsular switching.

279 ive ocular AEs included 119 (0.55%) cases of capsular tear and 73 (0.34%) cases of vitreous loss.

280 The rate of posterior capsular tear was 0.6% (P = .035) compared to 2.6% in ba

281 ajor intraoperative complication-a posterior capsular tear-occurred in the intravenous group.

282 0.74 to 6.23; P = 0.16); however, posterior capsular tears were significantly more common in FLACS v

283 concentrations and higher rates of posterior capsular tears.

284 r-assisted cataract surgery, with the use of capsular tension devices.

285 ersus without simultaneous implantation of a capsular tension ring (CTR) and a toric lens (Tecnis Tor

286 atient was successfully treated using FLACS, capsular tension ring and intraocular lens (IOL) implant

287 intraocular lens in the capsular bag, with a capsular tension ring due to partial zonular dehiscence.

288 o was randomized to receive or not receive a capsular tension ring.

289 e capacities, many studies have investigated capsular thickness or the interaction of the capsule wit

290 han the equatorial zonule and that choice of capsular thickness values can influence the results from

291 carrying pneumococcal serotypes with greater capsular thickness, neutrophil resistance, and metabolic

292 ide range of angles of force application and capsular thickness.

293 vironment (aqueous and vitreous humors), the capsular tissue, and the intraocular lens (IOL) surfaces

294 enC) or Gram-positive group B Streptococcus, capsular type III (GBS-III) bacteria resulted in augment

295 rotection against nonencapsulated strains or capsular types outside vaccine coverage.

296 based on the sequences available for the 13 capsular types that are included in PCV13: 1, 3, 4, 5, 6

297 creased serotype assignment (100%) to all 10 capsular types.

298 red significantly in resistance profiles and capsular types; emergent pulsotype 2123 was associated w

299 used to perform multilocus sequence typing, capsular typing, and identification of virulence and ant

300 Capsular Vi-polysaccharide-protein conjugate vaccines (V